Namrata Savaliya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Namrata Savaliya has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bhavesh Bhavsar
Dynamic Biologics Inc., Monmouth Junction, NJ 08852, USA
1 shared publication - Bhupendra Gopalbhai Prajapati
Parul University
1 shared publication - Dignesh Khunt
School of Pharmacy, Gujarat Technological University, Gandhinagar 382028, India
1 shared publication - Eknath D. Ahire
MET’s Institute of Pharmacy, BKC, Affiliated to Savitribai Phule Pune University, Adgaon Nashik, Maharashtra, India- 422003
1 shared publication - Kalarav V. Makwana
Vidman Pharmaceuticals Pvt Ltd., Ahmedabad 380061, Gujarat, India
1 shared publication - Mandeep Kaur Banth
School of Pharmacy, Gujarat Technological University, Gandhinagar 382028, Gujarat, India
1 shared publication
Latest Publications
- Open Access
- 30 May 2025
- Published by MDPI AG in Applied Nano
- Vol. 6 (2) , 9
Protein-Bound Nano-Injectable Suspension: Unveiling the Promises and Challenges
Protein-bound nano-injectable solutions represent a cutting-edge advancement in nanomedicine, offering a versatile platform for precise and controlled drug delivery. By leveraging the biocompatibility and functional versatility of proteins such as albumin, gelatin, and casein, these nano systems enhance drug solubility, prolong circulation time, and improve site-specific targeting, which are particularly beneficial in cancer and inflammatory diseases. This review provides a comprehensive overview of their formulation strategies, physicochemical characteristics, and biological behavior. Emphasis is placed on therapeutic applications, regulatory considerations, fabrication techniques, and the underlying mechanisms of drug–protein interactions. This review also highlights improved pharmacokinetics and reduced systemic toxicity, while also critically addressing challenges like immunogenicity, protein instability, and production scalability. Recent FDA-approved formulations and emerging innovations in precision medicine and theranostics underscore the transformative potential of protein-based nanosuspensions in next-generation drug delivery systems.
- 30 May 2025
- Published by MDPI AG in Applied Nano
- Vol. 6 (2) , 9
Open AccessProtein-Bound Nano-Injectable Suspension: Unveiling the Promises and Challenges
Protein-bound nano-injectable solutions represent a cutting-edge advancement in nanomedicine, offering a versatile platform for precise and controlled drug delivery. By leveraging the biocompatibility and functional versatility of proteins such as albumin, gelatin, and casein, these nano systems enhance drug solubility, prolong circulation time, and improve site-specific targeting, which are particularly beneficial in cancer and inflammatory diseases. This review provides a comprehensive overview of their formulation strategies, physicochemical characteristics, and biological behavior. Emphasis is placed on therapeutic applications, regulatory considerations, fabrication techniques, and the underlying mechanisms of drug–protein interactions. This review also highlights improved pharmacokinetics and reduced systemic toxicity, while also critically addressing challenges like immunogenicity, protein instability, and production scalability. Recent FDA-approved formulations and emerging innovations in precision medicine and theranostics underscore the transformative potential of protein-based nanosuspensions in next-generation drug delivery systems.